MSD scores second win in patent fight over Keytruda

The pharma giant invalidates a university's patent while gaining FDA approval for a new subcutaneous version of Keytruda as it protects its $29.5-billion-a-year cancer drug ahead of a looming patent cliff.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amneal acquires biopharma ahead of $300bn patent wave

23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.

Americas

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

23 April 2026 Plaintiff alleges that a $6 billion rival probed its records system via a long-term customer, using confidential information to develop its product in the behavioural health tech space.

Americas

Squires refuses to resurrect HydraFacial patent review

22 April 2026 Decision underscores a growing deference to parallel rulings and tighter control over duplicate patent challenges.